Xeris Biopharma Holdings, Inc. XERS Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from Xeris Biopharma Holdings, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s return on assets?
- Xeris Biopharma Holdings, Inc. (XERS) reported return on assets of 3.4% in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s return on assets changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s return on assets increased by 124.6% year-over-year, from -13.8% to 3.4%.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s return on assets?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s return on assets has grown at a -76.7% compound annual growth rate (CAGR), from -53% to 0.2%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.